Literature DB >> 32687661

The role of RIPK3-regulated cell death pathways and necroptosis in the pathogenesis of cardiac ischaemia-reperfusion injury.

Luo Ying1,2,3, Juthipong Benjanuwattra1,2, Siriporn C Chattipakorn1,2, Nipon Chattipakorn1,2,3.   

Abstract

Despite advancements in management of acute myocardial infarction, this disease remains one of the leading causes of death. Timely reestablishment of epicardial coronary blood flow is the cornerstone of therapy; however, substantial amount of damage can occur as a consequence of cardiac ischaemia/reperfusion (I/R) injury. It has been previously proposed that the pathway leading to major cell death, apoptosis, is responsible for cardiac I/R injury. Nevertheless, there is compelling evidence to suggest that necroptosis, a programmed necrosis, contributes remarkably to both myocardial injury and microcirculatory dysfunction following cardiac I/R injury. Receptor-interacting protein kinase 1 (RIPK1), RIPK3, and mixed-lineage kinase domain-like pseudokinase (MLKL) are shown as the major mediators of necroptosis. In addition to the traditional perception that RIPK1/RIPK3/MLKL-dependent plasma membrane rupture is fundamental to this process, several RIPK3-related pathways such as endoplasmic reticulum stress and mitochondrial fragmentation have also been implicated in cardiac I/R injury. In this review, reports from both in vitro and in vivo studies regarding the roles of necroptosis and RIPK3-regulated necrosis in cardiac I/R injury have been collectively summarized and discussed. Furthermore, reports on potential interventions targeting these processes to attenuate cardiac I/R insults to the heart have been presented in this review. Future investigations adding to the knowledge obtained from these previous studies are needed in the pursuit of discovering the most effective pharmacological agent to improve cardiac I/R outcomes.
© 2020 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  RIPK3; cardiac; cell death; ischaemia/reperfusion; necroptosis; necrostatin-1

Year:  2020        PMID: 32687661     DOI: 10.1111/apha.13541

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  6 in total

1.  Ca2+/Calmodulin-Dependent Protein Kinase II Regulation by Inhibitor of Receptor Interacting Protein Kinase 3 Alleviates Necroptosis in Glycation End Products-Induced Cardiomyocytes Injury.

Authors:  Yuyun Hua; Jianan Qian; Ji Cao; Xue Wang; Wei Zhang; Jingjing Zhang
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 2.  Myocardial ischemia/reperfusion injury: Mechanisms of injury and implications for management (Review).

Authors:  Jianfeng He; Danyong Liu; Lixia Zhao; Dongcheng Zhou; Jianhui Rong; Liangqing Zhang; Zhengyuan Xia
Journal:  Exp Ther Med       Date:  2022-05-06       Impact factor: 2.751

Review 3.  Targeting necroptosis as therapeutic potential in chronic myocardial infarction.

Authors:  Chanon Piamsiri; Chayodom Maneechote; Natthaphat Siri-Angkul; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  J Biomed Sci       Date:  2021-04-09       Impact factor: 8.410

4.  Downregulation of RIP3 Improves the Protective Effect of ATF6 in an Acute Liver Injury Model.

Authors:  Mei-Ying Huang; Dian-Wei Wan; Jie Deng; Wen-Jie Guo; Yue Huang; Huan Chen; De-Lin Xu; Zhi-Gang Jiang; Yuan Xue; Yi-Huai He
Journal:  Biomed Res Int       Date:  2021-11-05       Impact factor: 3.411

5.  T1AM Attenuates the Hypoxia/Reoxygenation-Induced Necroptosis of H9C2 Cardiomyocytes via RIPK1/RIPK3 Pathway.

Authors:  Bo Wei; Hanbing Zhao; Bailong Hu; Lujun Dai; Guoning Zhang; Lili Mo; Niwen Huang; Changchao Zou; Bei Zhang; Haiyan Zhou; Wei Li; Xingde Liu
Journal:  Biomed Res Int       Date:  2022-02-28       Impact factor: 3.411

6.  Role of Necroptosis and Immune Infiltration in Human Stanford Type A Aortic Dissection: Novel Insights from Bioinformatics Analyses.

Authors:  Fuqiang Liu; Tao Wei; Lin Liu; Fangxia Hou; Cuixiang Xu; Hua Guo; Wei Zhang; Meijuan Ma; Yulian Zhang; Qi Yu; Junkui Wang
Journal:  Oxid Med Cell Longev       Date:  2022-04-16       Impact factor: 7.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.